Government-Owned Inventions; Availability for Licensing, 32969-32971 [2015-14095]
Download as PDF
<![CDATA[
32969
Federal Register / Vol. 80, No. 111 / Wednesday, June 10, 2015 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
response per
respondent
Number of
respondents
Submission type
Average
time per
response
Annual
hour
burden
Certification to Delay Results ..........................................................................
Extension Request ...........................................................................................
700
30
1
1
30/60
2
350
60
Total ..........................................................................................................
33,130
........................
........................
682,535
Dated: June 4, 2015.
David Sharlip,
Project Clearance Liaison, NLM, NIH.
[FR Doc. 2015–14169 Filed 6–9–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Corneal Diseases, Membrane
Transport, and Ocular Cancer.
Date: June 22, 2015.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Alessandra C Rovescalli,
Ph.D., Scientific Review Officer, National
Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Rm 5205
MSC7846, Bethesda, MD 20892, (301) 435–
1021, rovescaa@mail.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Biostatistical Methods and Research Design
Study Section.
Date: June 26, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
VerDate Sep<11>2014
16:46 Jun 09, 2015
Jkt 235001
Contact Person: Peter J. Kozel, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
Bethesda, MD 20892, 301–435–1116, kozelp@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Glioblastomas, Multiple Sclerosis,
Viruses, and Psychiatric Disorders.
Date: June 30, 2015.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Samuel C Edwards, Ph.D.,
IRG CHIEF, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5210, MSC 7846, Bethesda, MD
20892, (301) 435–1246, edwardss@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR14–066:
Limited Competition: Specific Pathogen Ffee
Macaque Colonies.
Date: June 30, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Robert Freund, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cancer Drug Development and
Therapeutics.
Date: July 8–9, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Lilia Topol, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–451–
0131, ltopol@mail.nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group;
Behavioral and Social Consequences of HIV/
AIDS Study Section.
Date: July 9–10, 2015.
Time: 8:00 a.m. to 5:00 p.m.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street
NW., Washington, DC 20036.
Contact Person: Mark P. Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–806–
6596, rubertm@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 4, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–14170 Filed 6–9–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
SUMMARY:
E:\FR\FM\10JNN1.SGM
10JNN1
32970
Federal Register / Vol. 80, No. 111 / Wednesday, June 10, 2015 / Notices
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Boron Amino Acid Mimetics for PET
Imaging of Cancer
Description of Technology: Available
for licensing and commercial
development as imaging agents for
positron emission tomography of cancer
are boramino acid compounds. The
inventors showed that mimetics created
by substituting the carboxylate group (COO-) of an amino acid with
trifluoroborate (-BF3-) are metabolically
stable and allow for the use of fluorene18 (18F) as the radiolabel. Using
boroamino acid for 18F-labeling allows
for integrating the 18F radiolabel into the
core molecular backbone rather than the
side-chains thus increasing the agent’s
target specificity. There is a direct
relationship between amino acid uptake
and cancer cell replication, where the
uptake is extensively upregulated in
most cancer cells. This uptake increases
as cancer progresses, leading to greater
uptake in high-grade tumors and
metastases. Amino acids act as signaling
molecules for proliferation and may also
reprogram metabolic networks in the
buildup of biomass. This invention
provides for an unmet need for traceable
amino acid mimics, including those
based on naturally-occurring amino
acids, which may be non-invasively
detected by imaging technology,
including for clinical diagnosis and
anti-cancer drug evaluation.
Potential Commercial Applications:
• Cancer imaging
• Anti-cancer drug development
Competitive Advantages:
• Fluorene-18 labeling
• Metabolic stability
Development Stage:
• Early-stage
• In vitro data available
• In vivo data available (animal)
Inventors: Xiaoyuan Chen and Zhibo
Liu (NIBIB)
Publications:
1. Liu Z, et al. Preclinical evaluation
of a high-affinity 18F-trifluoroborate
octreotate derivative for somatostatin
receptor imaging. J Nucl Med. 2014
Sep;55(9):1499–505. [PMID 24970911]
2. Liu Z, et al. (18)F-trifluoroborate
derivatives of [des-arg(10)]kallidin for
imaging bradykinin b1 receptor
expression with positron emission
tomography. Mol Pharm. 2015 Mar
2;12(3):974–82. [PMID 25629412]
Intellectual Property: HHS Reference
No. E–135–2015/0—US Provisional
Patent Application 62/155,085 filed
April 30, 2015
VerDate Sep<11>2014
16:46 Jun 09, 2015
Jkt 235001
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019 or
301–402–5579; shmilovm@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Biomedical
Imaging and Bioengineering is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize Boramino Acid Mimetics
for Use in Cancer Imaging. For
collaboration opportunities, please
contact Cecilia Pazman at pazmance@
nih.gov.
Resolution Enhancement for Light
Sheet Microscopy Systems
Description of Technology: The
invention pertains to a technique for
enhancing the resolution of images in
light sheet microscopy by adding
additional enhanced depth-of-focus
optical arrangements and high
numerical aperture objective lenses. The
technique employs an arrangement of
three objective lenses and a processor
for combining captured images. The
image composition utilizes the greater
resolving power of the third high
numerical aperture objective lens by
imaging the light sheet and enhanced
depth-of-focus arrangement resulting in
improved overall resolution of the light
sheet system. The depth of field
arrangement could be a simple
oscillation of the third objective, a
‘‘layer cake,’’ or cubic phase mask
component. Any loss in lateral
resolution that results from the depth of
field arrangement may be compensated
for by deconvolution. In some
embodiments, other optics, such as an
axicon or annular aperture, can provide
extended depth of field.
Potential Commercial Applications:
• High speed imaging
• Fast single cell and cellular
dynamics imaging
• Superresolution and single
molecule imaging
• 3D single particle tracking
• 3D superresolution imaging in thick
samples
Competitive Advantages: Resolution
enhancement in light microscopy
Development Stage: In vitro data
available
Inventors: Hari Shroff (NIBIB), Yicong
Wu (NIBIB), Sara Abrahamsson
Intellectual Property: HHS Reference
No. E–232–2014/0—US Application No.
62/054,484 filed September 24, 2014
Related Technology: HHS Reference
No. E–078–2011/0
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019 or
301–402–5579; shmilovm@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Biomedical
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Imaging and Bioengineering is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize Resolution Enhancement
Technique for Light Sheet Microscopy
Systems. For collaboration
opportunities, please contact Cecilia
Pazman at 301–594–4273 or pazmance@
nhlbi.nih.gov.
Device for Selective Partitioning of
Frozen Cellular Products
Description of Technology:
Cryopreservation using liquid nitrogen
frozen polyvinyl bags allows for storing
cellular materials for extended periods
while maintaining their activity and
viability. Such bags are commonly used
in the clinic to store blood products
including blood cells, plasma,
hematopoietic stem cells, umbilical cord
blood for future uses including
transplantation. These materials,
typically obtained in limited quantities,
may be of great therapeutic value, as is
the case of stem cells or cord blood
derived cells which can be used to
potentially treat a number of diseases.
Currently, even if only a small portion
of the cryopreserved sample is needed
the whole bag must be thawed, wasting
much of the sample or rendering the
remaining sample susceptible to
contamination since it cannot be
effectively refrozen or sterilized. The
present device meets an unmet need for
retrieving a portion of a frozen sample
stored in polyvinyl cryopreserved bags,
resealing the remainder of the sample
and preserving the cryopreserved state
and integrity of the rest of the cellular
product without compromising viability
and sterility.
Potential Commercial Applications:
• Cryopreservation
• Cellular Products
• Hematopoietic stem cells
• Umbilical cord blood
• iPSCs
• Transplantation
• Chronic spinal cord injury
• Neurological disorders
• Cancer immunotherapy
• Cell banking
• Cell replacement therapy
Competitive Advantages:
• Partitioning cryopreserved cell
products
• Maintenance of sterility of
partitioned product
• Maintenance of viability of
partitioned product
• Resealing of cryopreservation bag
• Multiple use of patient derived
cellular products
Development Stage: Prototype
Inventors: Richard Childs, Sumithira
Vasu, Herb Cullis, PJ Broussard, Kevin
E:\FR\FM\10JNN1.SGM
10JNN1
Federal Register / Vol. 80, No. 111 / Wednesday, June 10, 2015 / Notices
Clark, Eric Harting (all rights assigned to
the US Government)
Intellectual Property: HHS Reference
No. E–173–2009/0 • US Provisional App. 61/175,131
• Int’l App. PCT/US2010/033575
• Canadian App. 2,760,363
• EP App. 10719496.1
• IL App. 216085
• US Patent 8,790,597
• US Patent App. 14/305,578
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019 or
301–402–5579; shmilovm@mail.nih.gov
Collaborative Research Opportunity:
The National Heart, Lung, and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Device for Partitioning
Cryopreserved Cellular Products. For
collaboration opportunities, please
contact Cecilia Pazman, Ph.D. at 301–
594–4273 or pazmance@nhlbi.nih.gov.
Dated: June 4, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
[1651–0001]
Agency Information Collection
Activities: Cargo Manifest/Declaration,
Stow Plan, Container Status Messages
and Importer Security Filing
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: 30-Day notice and request for
comments; Extension of an existing
collection of information.
AGENCY:
U.S. Customs and Border
Protection (CBP) of the Department of
Homeland Security will be submitting
the following information collection
request to the Office of Management and
Budget (OMB) for review and approval
in accordance with the Paperwork
Reduction Act: Cargo Manifest/
Declaration, Stow Plan, Container Status
Messages and Importer Security Filing.
CBP is proposing to add burden hours
for four new collections of information,
including Electronic Ocean Export
Manifest, Electronic Air Export
Manifest, Electronic Rail Export
Manifest, and Vessel Stow Plan
(Export). There are no changes to the
asabaliauskas on DSK5VPTVN1PROD with NOTICES
VerDate Sep<11>2014
16:46 Jun 09, 2015
Jkt 235001
Written comments should be
received on or before July 10, 2015 to be
assured of consideration.
DATES:
Interested persons are
invited to submit written comments on
this proposed information collection to
the Office of Information and Regulatory
Affairs, Office of Management and
Budget. Comments should be addressed
to the OMB Desk Officer for Customs
and Border Protection, Department of
Homeland Security, and sent via
electronic mail to oira_submission@
omb.eop.gov or faxed to (202) 395–5806.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Requests for additional information
should be directed to Tracey Denning,
U.S. Customs and Border Protection,
Regulations and Rulings, Office of
International Trade, 90 K Street NE.,
10th Floor, Washington, DC 20229–
1177, at 202–325–0265.
This
proposed information collection was
previously published in the Federal
Register (80 FR 17059) on March 31,
2015, allowing for a 60-day comment
period. This notice allows for an
additional 30 days for public comments.
This process is conducted in accordance
with 5 CFR 1320.10. CBP invites the
general public and other Federal
agencies to comment on proposed and/
or continuing information collections
pursuant to the Paperwork Reduction
Act of 1995 (Pub. L. 104–13; 44 U.S.C.
3507). The comments should address:
(a) Whether the collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s
estimates of the burden of the collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; (d) ways to
minimize the burden, including the use
of automated collection techniques or
the use of other forms of information
technology; and (e) the annual costs to
respondents or record keepers from the
collection of information (total capital/
startup costs and operations and
maintenance costs). The comments that
are submitted will be summarized and
included in the CBP request for OMB
approval. All comments will become a
matter of public record. In this
document, CBP is soliciting comments
concerning the following information
collection:
SUPPLEMENTARY INFORMATION:
[FR Doc. 2015–14095 Filed 6–9–15; 8:45 am]
SUMMARY:
existing forms or collections within this
OMB approval. This document is
published to obtain comments from the
public and affected agencies.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
32971
Title: Cargo Manifest/Declaration,
Stow Plan, Container Status Messages
and Importer Security Filing.
OMB Number: 1651–0001.
Form Numbers: Forms 1302, 1302A,
7509, 7533.
Abstract: This OMB approval
includes the following existing
information collections: CBP Form 1302
(or electronic equivalent); CBP Form
1302A (or electronic equivalent); CBP
Form 7509 (or electronic equivalent);
CBP Form 7533 (or electronic
equivalent); Manifest Confidentiality;
Vessel Stow Plan (Import); Container
Status Messages; and Importer Security
Filing. CBP is proposing to add new
information collections for Electronic
Ocean Export Manifest; Electronic Air
Export Manifest; Electronic Rail Export
Manifest; and Vessel Stow Plan
(Export). Specific information regarding
these collections of information is as
follows:
CBP Form 1302: The master or
commander of a vessel arriving in the
United States from abroad with cargo on
board must file CBP Form 1302, Inward
Cargo Declaration, or submit the
information on this form using a CBPapproved electronic equivalent. CBP
Form 1302 is part of the manifest
requirements for vessels entering the
United States and was agreed upon by
treaty at the United Nations Intergovernment Maritime Consultative
Organization (IMCO). This form and/or
electronic equivalent, is provided for by
19 CFR 4.5, 4.7, 4.7a, 4.8, 4.33, 4.34,
4.38, 4.84, 4.85, 4.86, 4.91, 4.93 and 4.99
and is accessible at: https://
www.cbp.gov/sites/default/files/
documents/CBP%20Form%201302_
0.pdf.
CBP Form 1302A: The master or
commander of a vessel departing from
the United States must file CBP Form
1302A, Cargo Declaration Outward With
Commercial Forms, or CBP-approved
electronic equivalent, with copies of
bills of lading or equivalent commercial
documents relating to all cargo
encompassed by the manifest. This form
and/or electronic equivalent, is
provided for by 19 CFR 4.62, 4.63, 4.75,
4.82, and 4.87–4.89 and is accessible at:
https://www.cbp.gov/sites/default/files/
documents/CBP%20Form%201302_
0.pdf.
Electronic Ocean Export Manifest:
CBP will begin a pilot in 2015 to
electronically collect ocean export
manifest information. This information
will be transmitted to CBP in advance
via the Automated Export System (AES)
within the Automated Commercial
Environment (ACE). The data elements
to be transmitted may include the
following:
E:\FR\FM\10JNN1.SGM
10JNN1
]]>Agencies
[Federal Register Volume 80, Number 111 (Wednesday, June 10, 2015)]
[Notices]
[Pages 32969-32971]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-14095]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will
[[Page 32970]]
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Boron Amino Acid Mimetics for PET Imaging of Cancer
Description of Technology: Available for licensing and commercial
development as imaging agents for positron emission tomography of
cancer are boramino acid compounds. The inventors showed that mimetics
created by substituting the carboxylate group (-COO-) of an
amino acid with trifluoroborate (-BF3-) are
metabolically stable and allow for the use of fluorene-18 (\18\F) as
the radiolabel. Using boroamino acid for \18\F-labeling allows for
integrating the \18\F radiolabel into the core molecular backbone
rather than the side-chains thus increasing the agent's target
specificity. There is a direct relationship between amino acid uptake
and cancer cell replication, where the uptake is extensively
upregulated in most cancer cells. This uptake increases as cancer
progresses, leading to greater uptake in high-grade tumors and
metastases. Amino acids act as signaling molecules for proliferation
and may also reprogram metabolic networks in the buildup of biomass.
This invention provides for an unmet need for traceable amino acid
mimics, including those based on naturally-occurring amino acids, which
may be non-invasively detected by imaging technology, including for
clinical diagnosis and anti-cancer drug evaluation.
Potential Commercial Applications:
Cancer imaging
Anti-cancer drug development
Competitive Advantages:
Fluorene-18 labeling
Metabolic stability
Development Stage:
Early-stage
In vitro data available
In vivo data available (animal)
Inventors: Xiaoyuan Chen and Zhibo Liu (NIBIB)
Publications:
1. Liu Z, et al. Preclinical evaluation of a high-affinity 18F-
trifluoroborate octreotate derivative for somatostatin receptor
imaging. J Nucl Med. 2014 Sep;55(9):1499-505. [PMID 24970911]
2. Liu Z, et al. (18)F-trifluoroborate derivatives of [des-
arg(10)]kallidin for imaging bradykinin b1 receptor expression with
positron emission tomography. Mol Pharm. 2015 Mar 2;12(3):974-82. [PMID
25629412]
Intellectual Property: HHS Reference No. E-135-2015/0--US
Provisional Patent Application 62/155,085 filed April 30, 2015
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019 or
301-402-5579; shmilovm@mail.nih.gov
Collaborative Research Opportunity: The National Institute of
Biomedical Imaging and Bioengineering is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Boramino Acid
Mimetics for Use in Cancer Imaging. For collaboration opportunities,
please contact Cecilia Pazman at pazmance@nih.gov.
Resolution Enhancement for Light Sheet Microscopy Systems
Description of Technology: The invention pertains to a technique
for enhancing the resolution of images in light sheet microscopy by
adding additional enhanced depth-of-focus optical arrangements and high
numerical aperture objective lenses. The technique employs an
arrangement of three objective lenses and a processor for combining
captured images. The image composition utilizes the greater resolving
power of the third high numerical aperture objective lens by imaging
the light sheet and enhanced depth-of-focus arrangement resulting in
improved overall resolution of the light sheet system. The depth of
field arrangement could be a simple oscillation of the third objective,
a ``layer cake,'' or cubic phase mask component. Any loss in lateral
resolution that results from the depth of field arrangement may be
compensated for by deconvolution. In some embodiments, other optics,
such as an axicon or annular aperture, can provide extended depth of
field.
Potential Commercial Applications:
High speed imaging
Fast single cell and cellular dynamics imaging
Superresolution and single molecule imaging
3D single particle tracking
3D superresolution imaging in thick samples
Competitive Advantages: Resolution enhancement in light microscopy
Development Stage: In vitro data available
Inventors: Hari Shroff (NIBIB), Yicong Wu (NIBIB), Sara Abrahamsson
Intellectual Property: HHS Reference No. E-232-2014/0--US
Application No. 62/054,484 filed September 24, 2014
Related Technology: HHS Reference No. E-078-2011/0
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019 or
301-402-5579; shmilovm@mail.nih.gov
Collaborative Research Opportunity: The National Institute of
Biomedical Imaging and Bioengineering is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Resolution
Enhancement Technique for Light Sheet Microscopy Systems. For
collaboration opportunities, please contact Cecilia Pazman at 301-594-
4273 or pazmance@nhlbi.nih.gov.
Device for Selective Partitioning of Frozen Cellular Products
Description of Technology: Cryopreservation using liquid nitrogen
frozen polyvinyl bags allows for storing cellular materials for
extended periods while maintaining their activity and viability. Such
bags are commonly used in the clinic to store blood products including
blood cells, plasma, hematopoietic stem cells, umbilical cord blood for
future uses including transplantation. These materials, typically
obtained in limited quantities, may be of great therapeutic value, as
is the case of stem cells or cord blood derived cells which can be used
to potentially treat a number of diseases. Currently, even if only a
small portion of the cryopreserved sample is needed the whole bag must
be thawed, wasting much of the sample or rendering the remaining sample
susceptible to contamination since it cannot be effectively refrozen or
sterilized. The present device meets an unmet need for retrieving a
portion of a frozen sample stored in polyvinyl cryopreserved bags,
resealing the remainder of the sample and preserving the cryopreserved
state and integrity of the rest of the cellular product without
compromising viability and sterility.
Potential Commercial Applications:
Cryopreservation
Cellular Products
Hematopoietic stem cells
Umbilical cord blood
iPSCs
Transplantation
Chronic spinal cord injury
Neurological disorders
Cancer immunotherapy
Cell banking
Cell replacement therapy
Competitive Advantages:
Partitioning cryopreserved cell products
Maintenance of sterility of partitioned product
Maintenance of viability of partitioned product
Resealing of cryopreservation bag
Multiple use of patient derived cellular products
Development Stage: Prototype
Inventors: Richard Childs, Sumithira Vasu, Herb Cullis, PJ
Broussard, Kevin
[[Page 32971]]
Clark, Eric Harting (all rights assigned to the US Government)
Intellectual Property: HHS Reference No. E-173-2009/0 -
US Provisional App. 61/175,131
Int'l App. PCT/US2010/033575
Canadian App. 2,760,363
EP App. 10719496.1
IL App. 216085
US Patent 8,790,597
US Patent App. 14/305,578
Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019 or
301-402-5579; shmilovm@mail.nih.gov
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize Device for Partitioning Cryopreserved
Cellular Products. For collaboration opportunities, please contact
Cecilia Pazman, Ph.D. at 301-594-4273 or pazmance@nhlbi.nih.gov.
Dated: June 4, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-14095 Filed 6-9-15; 8:45 am]
BILLING CODE 4140-01-P
